uPA and PAI-1: Clinically and technically validated prognostic markers in breast cancer  by Duffy, M.J.
PMA-induced, K-ras- and Src-induced gene expression. New data
will be presented in this lecture showing that the newly character-
ized tumor suppressor Pdcd4 suppresses u-PAR gene expression,
this again in part being mediated by Sp3 bound to the 152/
135 motif.
Furthermore, the lecture will focus on the differential binding
of transcription factors to both u-PAR promoter elements in vivo,
having been investigated in a large series of resected tumor and
normal tissue of colorectal and gastric cancer patients. We will
demonstrate that, depending on the transcription factor and cis-
element, patient subgroups of different size can be selected in
which transactivation via these promoter elements might be
tumor-tissue-specific, suggesting subgroups for tumor-selective
targeting. Also, the lecture will outline that different u-PAR-pro-
moter motifs may be of different tumor-specificity in vivo. We will
also suggest patient subgroups in which a synergistic regulation
of u-PAR gene expression in resected tissues via both promoter
elements can be postulated. Finally, first data on a clinical-prog-
nostic relevance of differential transcription factor binding to
specific u-PAR-promoter motifs will be shown, suggesting the
binding of, for example, Sp1, and transcription factor combina-
tions out of Sp1/AP-2 and AP-1-binding as new and independent
predictors of disease-specific survival. A first molecularly
extended staging model will be presented from these data. Poten-
tial conclusions for a more target-oriented patient selection and
therapy out of transcriptional and oncogeneic regulators of the
uPA-R gene will be discussed.
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VALIDATED PROGNOSTIC MARKERS IN BREAST CANCER
M.J. Duffy. St Vincent’s University Hospital, Dublin, Ireland.
For optimum management of patients with cancer, accurate
prognostic factors are required. The primary determinant of out-
come in patients with malignancy is cancer progression, espe-
cially the formation of distant metastases. Based on data from
model systems, urokinase plasminogen activator (uPA) is one of
the critical mediators of cancer progression. uPA appears to
mediate progression via multiple mechanisms including remod-
elling of the extracellular matrix, enhancing cell proliferation
and migration and modulating cell adhesion. PAI-1, although
originally identified as an inhibitor of uPA, is also causally
involved in cancer progression. Consistent with their roles in
cancer progression, multiple independent studies have shown
that elevated levels of uPA and PAI-1 predict poor prognosis in
patients in breast cancer. The prognostic impact of uPA and
PAI-1 is potent (e.g., RR > 2.0), independent of standard prognostic
factors and found in both lymph node-negative and lymph node-
positive disease. Importantly, the prognostic impact of uPA/PAI-1
has been validated in both a randomized prospective trial and a
pooled analysis, i.e., in 2 level I evidence studies. In addition to
clinical validation, specific ELISA for uPA and PAI-1 have under-
gone technical validation including validation in an external
quality assurance program. uPA and PAI-1 are thus now ready
for clinical application, especially in the identification of newly
diagnosed breast cancer patients that may be able to avoid hav-
ing to receive adjuvant chemotherapy.
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Cancer cells usually have a distinct morphological and genetic
profile that allows to determine between reactive, premalignant
and malignant lesions. In some tumor entities, however, morpho-
logical and expression profiles do not necessarily reflect the true
nature of the putative lesion. Molecular biological advances could
further clarify the biological potential in some tumor entities, in
others however, morphological and topographical criteria are still
crucial, since no evident typical molecular profiles could be deter-
mined so far.
Prostate cancer is a prominent example of cancer where exo-
crine and neuroendocrine (NE) tumor cells can occur within the
same tumor. The role of these NE cells is still under debate, even
the question of its neoplastic nature and its biological signifi-
cance. Since in these NE cells no proliferation could be demon-
strated so far, NE tumor cells in prostate cancer are regarded as
post-mitotic and their significance has been regarded as ‘low’.
The interesting question is, therefore, whether a post-mitotic
cancer cell still deserves the attribute ‘‘cancer cell’’ and what
are its biological functions in the cancerous orchestration.
Although molecular and clinical data seem to give evidence that
NE tumor cells are the result of a transdifferentiation process
and possess a prognostic significance, their final role in vivo is
not yet completely understood.
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Matrix metalloproteinases (MMPs) are important in cancer dis-
semination by virtue of degradation of extracellular matrix, as
well as diverse effects on cell growth, apoptosis, migration,
and angiogenesis. Negative results from clinical drug trials of
MMP inhibitors in advanced cancers has refocused attention
on the role of MMPs in early cancer development. Experimental
and clinical evidence suggests that membrane type 1-matrix
metalloproteinase (MT1-MMP) may serve as a master regulator
of cancer progression. The mechanism underlying this process
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